Schonfeld Strategic Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-97,529	Closed	-$2.37M	–	2111
2025 Q1	$2.37M	Buy	97,529 +24,549	+34%	+$553K	0.01%	881
2024 Q4	$1.52M	Buy	+72,980	New	+$1.57M	0.01%	945
2024 Q1	–	Sell	-16,887	Closed	-$284K	–	2118
2023 Q4	$284K	Buy	+16,887	New	+$231K	﹤0.01%	1444
2022 Q4	–	Sell	-176,506	Closed	-$2.27M	–	2654
2022 Q3	$2.27M	Buy	+176,506	New	+$2.09M	0.02%	812
2022 Q2	–	Sell	-23,288	Closed	-$193K	–	2610
2022 Q1	$193K	Buy	+23,288	New	+$165K	﹤0.01%	1995
2018 Q1	–	Sell	-38,997	Closed	-$153K	–	789
2017 Q4	$153K	Buy	+38,997	New	+$129K	0.01%	689

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Schonfeld Strategic Advisors's CPRX Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 97,529 shares — an estimated $2.37M sold.

Schonfeld Strategic Advisors first reported a position in CPRX in Q4 2017 and held it in 6 quarters. The position peaked at $2.37M in Q1 2025. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

Schonfeld Strategic Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Schonfeld Strategic Advisors sold 97,529 Catalyst Pharmaceutical shares in Q2 2025, an estimated $2.37M.
Schonfeld Strategic Advisors first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 6 quarters.
Schonfeld Strategic Advisors's Catalyst Pharmaceutical position peaked at $2.37M in Q1 2025.
365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.